SOURCES SOUGHT
B -- OND Workload Analysis and OODP Restructuring
- Notice Date
- 6/5/2009
- Notice Type
- Sources Sought
- NAICS
- 541990
— All Other Professional, Scientific, and Technical Services
- Contracting Office
- Department of Health and Human Services, Food and Drug Administration, Office of Acquisitions and Grants Services, 5630 Fishers Lane, Room 2129, Rockville, Maryland, 20857-0001
- ZIP Code
- 20857-0001
- Solicitation Number
- HHS-FDA-SS-09-1057585
- Archive Date
- 6/26/2009
- Point of Contact
- Tara R. Hobson, Phone: 3018279691, Doreen Williams , Phone: 301-827-3366
- E-Mail Address
-
Tara.Hobson@fda.hhs.gov, doreen.williams@fda.hhs.gov
(Tara.Hobson@fda.hhs.gov, doreen.williams@fda.hhs.gov)
- Small Business Set-Aside
- N/A
- Description
- Description: Reorganizing the Office of Oncology Drug Products This is a SOURCES SOUGHT NOTICE to determine the availability and capability of small businesses (including certified 8(a), Small Disadvantaged, and HUBZone firms; veteran and service-disabled veteran-owned small businesses, and woman-owned small businesses). This notice is being posted for fact finding and planning purposes only and shall not be construed as an Invitation for Bid, a Request for Proposal, Solicitation, Request for Quotes, or an indication the Government will contract for the items or services herein. This notice is not to be construed as a commitment on the part of the Government to award a contract, nor does the Government intend to pay for any information submitted as a result of this notice. The Government does not reimburse respondents for any cost associated with submission of the information being requested or reimburse expenses incurred to interested parties for responses to this source sought. Any response received will not be used as a proposal. No official solicitation currently exists in connection to this request for information (RFI). Also, if in the future an official solicitation is released, there is no guarantee that sources responding to this RFI will be included on the source list. **QUESTIONS WILL NOT BE ENTERTAINED AS A RESULT OF THIS NOTICE** The Food and Drug Administration (FDA), Office of Acquisitions and Grants Services (OAGS), Division of Acquisition Operations (DAO) is to seeking to identify sources with capabilities and prior experience in Workload Analysis Tool for reevaluation, revamping and restructuring the Office of Oncology Drug Products. Objectives: The ultimate goal of this project is to obtain a qualified contractor to provide executive level consulting services, program design, development, and implementation services to comprehensively support revamping the workload analysis tool and implementation of process improvements and reorganization for the Office of Oncology Drug Products (OODP). The work is to be performed at the Food and Drug Administration, Center for Drug Evaluation and Research (CDER), at CDER’s White Oak facility located in Silver Spring, Maryland. Draft Scope of Work: The contractor shall provide all necessary qualified, experienced personnel to carry out the tasks outlined below. The contractor shall work with the Director of OODP to provide expert assistance in accomplishing the tasks below: Demonstrate clear and detailed understanding of the work processes of the Office of New Drugs and OODP. Facilitate the work and functioning within the office. Develop recommendations for a new office structure. Develop and deliver training modules and facilitated events to implement new structure. Develop a plan for reanalysis of the current OND Workload Analysis Tool and conduct interviews, facilitate meetings and work with workload analysis data to develop a revised Workload Analysis Tool. Develop questionnaires, conduct interviews, record and synthesize interview data about OODP. The contractor will also collect OODP workload data to be used to develop recommendations for a workload model and structure. Identify deficiencies of current organization structure, collaboration practices and any residual problems caused by the integration of biologics into OODP. Identify changes to overall structure of OODP staff and develop recommendations for the future state. Identify detailed implementation activities to achieve the future state for OODP. Develop and deliver training to introduce the new structure and prepare staff for their new roles within OODP. Apply communication plans; work with leadership on working to deliver key messages and guiding the reorganization of OOD The contractor will provide support and assistance for the initiative throughout the duration of the contract. This will include, but not be limited to, responding to questions and requests for assistance from top management, supervisors, and the change activity staff. The FDA anticipates using a labor hour type contract for two years. Viable parties shall provide the following: Part A. Capabilities and Technical Experience – Provide a capability statement describing how your company would provide executive level consulting services, program design, development, and implementation services to comprehensively support revamping the workload analysis tool and implementation of process improvements and reorganization for the Office of Oncology Drug Products (OODP). Part B. Size of Business- Please provide your business size and submit copies of any documentation such as letters or certificates to indicate the firm’s status. Part C. Organizational Conflict of Interest (OCI) - If any, provide disclosure of business activities of your company, your affiliates, your team members and affiliates of your team members which create either a conflict of interest or the appearance of a conflict of interest in the performance of the possible work listed above. Part D. Cost Estimate - Provide a cost estimate for the services (i.e. hourly rates, hours/days) and the number of hours for restructuring the Office of Oncology Drug Products. Cost should consist of the type of personnel need, hourly rate/days, material and travel expense if applicable or related to the proposed project. Part E. Small Business – Describe your ability to meet the requirements in accordance with 52.219.14 – Limitation on Subcontracting. Responses shall adhere to the following: 1. Reference the Sources Sought number when submitting Capability Statement. 2. The capability statement shall be no more than five (5) pages in length. 3. The marketing materials shall not be included. 4. The capability statement shall be e-mailed to the attention of the Contract Specialist listed above. FDA makes no implied or in fact contract by issuing this Sources Sought. Acknowledgement of receipt of responses will not be made, nor will respondents be notified of the FDA’s view of the information received. Do not send any material that requires a non-disclosure agreement or that may be business sensitive. Responses received that include a non-disclosure agreement or identify information that is business sensitive will not be accepted. Responses to this notice will not be returned.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/FDA/DCASC/HHS-FDA-SS-09-1057585/listing.html)
- Place of Performance
- Address: FDA, CDER, 10903 New Hampshire Ave, Silver Spring, Maryland, 20993, United States
- Zip Code: 20993
- Zip Code: 20993
- Record
- SN01837395-W 20090607/090605235206-40d3349f8fb72d4180e86e866bb1bef2 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |